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One of the key questions in the study of mammalian
gene regulation is how epigenetic methylation patterns
on histones andDNAare initiated and established. These
stable, heritable, covalent modifications are largely
associated with the repression or silencing of gene tran-
scription, and when deregulated can be involved in the
development of human diseases such as cancer. This
article reviews examples of viruses and bacteria known
or thought to induce epigenetic changes in host cells,
and how this might contribute to disease. The heritable
nature of these processes in gene regulation suggests
that they could play important roles in chronic diseases
associated with microbial persistence; they might also
explain so-called ‘hit-and-run’ phenomena in infectious
disease pathogenesis.
Background on epigenetics
An epigenetic trait was recently defined as ‘a stably heri-
table phenotype resulting from changes in a chromosome
without alterations in theDNA sequence’ [1]. Such changes
are mediated by chemical modifications to chromatin on
both DNA and DNA-associated histones (see Glossary).
Posttranslational covalent modifications to the flexible
NH2 terminus (tail) of histones include methylation, acety-
lation, phosphorylation and ubiquitylation, and these are
associated with the structural organization of chromatin
and its transcriptional status. However, not all histone
modifications are truly epigenetic, as very few satisfy the
heritable part of the definition. To establish and mediate
epigenetic memory, such modifications must be trans-
mitted during DNA replication [1–3]. Methylation of cyto-
sine in CpG dinucleotides (often referred to as DNA
methylation) also contributes to the epigenetic status of
a gene locus.When this occurs in a CpG island adjacent to a
transcription initiation site, it is generally associated with
repression or silencing of transcription. Histone modifi-
cation, DNA methylation and the resulting reorganisation
of chromatin are closely interlinked enzyme-driven pro-
cesses that determine the transcriptional status of genes,
gene clusters and noncoding RNAs such as micro ((mi)R-
NAs (Figure 1). Most of the epigenetic markers mentioned
above are associated with transcriptional repression.
Multiple additional covalent modifications to histones
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Glossary
Chromatin immunoprecipitation (ChIP): central to the study of epigenetic
modifications, this is a technique that allows the specific precipitation of DNA
sequences associated with chromatin-bound proteins, notably histones with
specific epigenetic modifications. There are now hundreds of widely available
verified antibodies that can be used for ChIP, which are also available as
standardized ChIP kits.
CpG island: a region of DNA that contains the sequence CG more frequently
than predicted in a random distribution of bases. When they are at the
promoter of active genes, they are largely protected from DNA methylation.
CpG DNA methylation: the addition of a methyl group at position 5 of the
aromatic ring in cytosine, which can occur when a cytosine is followed by a
guanine in the DNA sequence. Generally associated with transcriptional
repression, especially when found at gene promoters.
Deep sequencing: the concurrent sequencing of millions of molecules from a
DNA library. The method is based on producing separate clusters of amplified,
individual molecules for the original library, in single stranded (ss)DNA form.
Nucleotides are incorporated onto ssDNA, according to DNA complementarity,
which produces a light signal that can be read by an instrument. Successive
rounds of incorporation allow reading the sequences of millions of clusters at
the same time, according to the light signals emitted at each cluster position.
DNA methyltransferase (DNMT): enzymes mediating CpG DNA methylation. In
humans, DNMT3a and DNMT3b are de novo DNMTs. DNMT1 is considered
responsible for the maintenance of DNA methylation patterns because it is
preferentially targeted to DNA that is methylated on one strand (hemimethy-
lated) after replication to restore methylation on the newly synthesized strand.
Histone: Histones are proteins comprising the basic chromatin structural unit,
the nucleosome. Histones H2A, H2B, H3 and H4 form an octamer (two copies of
each) core, around which DNA winds 1.7 times to form the coiled nucleosome
structure. Histones of the histone core have two functional domains, the
characteristic histone fold that is necessary for histone–histone/DNA interac-
tions and an NH2-terminal tail that protrudes from the nucleosome core.
Histone deacetylase (HDAC): enzymes mediating deacetylation at various
lysine residues of histone tails. There are three classes of HDACs: class I and II
HDACs are zinc-dependent and class III HDACs are NAD-dependent. Most of
these enzymes do not show high preference for specific lysine residues.
Polycomb group (PcG) proteins: these were first identified in Drosophila and
are best known as repressors of the homeotic (Hox) transcription factor genes
during embryonic development, from flies to humans. They form multiprotein
complexes called polycomb repressive complexes (PRCs) that bind and
epigenetically regulate hundreds of genes, predominantly associated with
cell-fate decisions and development.
Polycomb repressive complex (PRC)1: a complex that mediates the repressive
ubiquitination at lysine 119 of histone H2A (H2AK119Ub). Core proteins include
chromobox proteins, whose chromodomains are thought to recruit the
complex to the H3K27me3 mark, and RING finger proteins, such as RING1B
and BMI1, which are responsible for the E3 ubiquitin ligase activity of the
complex at H2AK119.
Polycomb repressive complex (PRC)2: a complex that mediates trimethylation
at lysine 27 of histone H3 (H3K27me3). In humans the core complex comprises
three polycomb proteins: suppressor of zeste (SUZ)12, embryonic ectoderm
development (EED) and enhancer of zeste (EZH)2. EZH2 contains the catalytic
SET domain core, whereas both SUZ12 and EED are required to maintain
complex integrity and the enzymatic activity of EZH2.
SET domain: protein domain responsible for lysine methyltransferase activity
in many proteins. It is found in proteins of organisms as diverse as archaea,
Open access under CC BY license.bacteria and humans, possibly as a result of horizontal transfer. EZH2, whichexist in parallel to these, resulting in a complex and
catalyses H3K27 methylation, and G9a and Suv39H1, which catalyse H3K9
methylation, are examples of proteins with SET domains.
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Figure 1. Histone modifications play at least two roles in the establishment of the epigenetic landscape of a cell. They can act as heritable repressive marks that compact
chromatin and inhibit transcription of specific genes or loci, but they can also focus DNMTs to chromatin, thus establishing the more stable epigenetic mark CpG
methylation. In general, regions permissive for transcription have ‘open’ active chromatin, marked by hyperacetylation of histones H3 and H4 at multiple sites and
trimethylation of histone H3 at lysine 4 (H3K4me3, not shown). HDAC remove acetyl groups (Ac) from H3 and H4, and at least two complexes initiate further repressive
histone modifications. (a) Complexes containing one or both of the histone methyltransferases G9a and SUV39H1 are responsible for trimethylation of H3 at lysine 9
(H3K9me3), establishing chromatin in a ‘closed’ repressive state. H3K9me3 then recruits the heterochromatin-protein HP1 to form heterochromatin; G9a, SUV39H1, HDACs
and HP1 are all capable of binding and recruiting DNMTs, which can then facilitate CpG methylation ([89–92] and references therein). Methyl cytosines established by the
DNMTs serve as docking sites for methyl-CpG binding domain (MBD) proteins such as MeCP2. (b) Polycomb-mediated repression facilitates a second repressive
modification. PRC2 is composed of SUZ12, EED and the H3 lysine 27 methyltransferase EZH2, which establishes the H3K27me3 mark. H3K27me3 recruits PRC1, which
includes BMI1 and RING1B and is responsible for the additional repressive modification of ubiquitinylation of histone H2A at lysine 119 (H2AK119Ub, not shown).
Components of PRC1 (BMI1) and PRC2 (EZH2) and HDACs physically associate with DNMTs and also provide a platform for CpG methylation [4,6,82]. Again, MBD proteins
such as MeCP2 bind and consolidate the repression or silencing.
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tional state [2]. Becausemost of thesemodifications are not
strictly epigenetic (i.e. heritable), and space constraints
limit the scope of this review, they will not be considered
further.
Epigenetic processes have been heavily implicated in
the development of cancer, in which repression or silencing
of tumour suppressor genes is remarkably common (Box 1)
[4–6]. A reasonable hypothesis stemming from this is that
pathogens associated with the development of cancer
might initiate or influence the epigenetic processes of host
cells, leading to epigenetic reprogramming. Evidence is
accumulating that this is the case, and might be a wide-
spread phenomenon [7]. In addition, pathogens might
manipulate epigenetic processes to influence host
responses associated with immunity and inflammation,
and to contribute to other forms of chronic disease.
The aim of this paper is to briefly review examples of
epigenetic control of host genes by viral and bacterial
pathogens, and highlight how this could be relevant in
disease pathogenesis.
Viral manipulation of host epigenetic marks
As obligate intracellular parasites, viruses have developed
numerous ways of hijacking cell processes to facilitate the
completion of their life cycle and sometimes to evade the
immune responses of their host. Viruses that cause per-
sistent (often latent) infections are likely to benefit from
heritable epigenetic changes in host transcription that440produce an environment for their latent or persistent state
without having to continuously express the initiating effec-
tors [8]. Host genes involved in cell cycle progression,
senescence, survival, inflammation and immunity are
prime candidates as targets for such epigenetic control.
We use two human g-herpesviruses, Kaposi’s sarcoma-
associated virus (KSHV or HHV8) and Epstein–Barr virus
(EBV), to illustrate how epigenetic manipulation of host
cells probably contributes to latency and is likely to be
involved in disease pathogenesis. Other less well-charac-
terised examples will then be described.
KSHV
KSHV has a distinct tropism for B lymphocytes, but it also
infects endothelial cells. Similar to EBV,KSHV establishes
life-long latency in humans, but unlike EBV, the specific
cell type in which it remains latent is unknown. As the
name indicates, the virus is associated with Kaposi’s sar-
coma, but also with primary effusion lymphoma (PEL) and
multicentric Castleman’s disease), two rare forms of B cell
lymphoma [9]. KSHV encodes a latency associated nuclear
antigen (LANA), and this protein is invariably expressed in
latently infected cells and can interact with cellular DNA
methyltransferases (DNMTs). Bacterially expressed gluta-
thione s-transferase-LANA binds to DNMT1, DNMT3A
and DNMT3B in vitro, but LANA appears to interact
preferentially with DNMT3A in vivo [10]. LANA was
identified by chromatin immunoprecipitation (ChIP)
analysis at promoters of cell genes whose transcription
Box 1. PcG proteins and DNA methylation: cancer, aging
and inflammation
PcG proteins are transcriptional repressors that play crucial roles in
development and differentiation (Figure 1). Stem cells and cancer
cells often share gene expression patterns, and PcG proteins are
thought to be essential for the maintenance of stem cells and in
oncogenesis [4,6,82]. Multiple reports suggest that PcG complexes
contribute to the aberrant methylation profiles that are crucial in the
genesis and progression of diverse cancers [83–85]. The mechanism
for this is suggested by the capacity of PcG proteins to physically
interact with DNMTs and recruit them to chromatin (Figure 1). It has
been estimated that PcG target genes are up to 12 times more likely
to become aberrantly methylated than non-targets [85]. However, it
should be noted that polycomb-mediated gene silencing in cancer
can also be independent of DNA methylation, and that DNA
methylation is not an inevitable consequence of polycomb-asso-
ciated histone modifications [86].
In Drosophila, repression by PcG spreads from polycomb
response elements (PREs) located in a genomic regulatory locus,
but the direct equivalents of PREs have not been identified in
mammalian cells. The mechanism by which PcGs are targeted to
specific chromatin loci is unknown and is a key problem in
mammalian biology. The most likely candidates for PcG recruiting
factors are sequence-specific transcription factors and/or long
noncoding RNAs, either of which could be deregulated in cancer
or other chronic diseases [4,6,82,87].
Recent reports indicate that both normal ageing and chronic
inflammation contribute to the aberrant methylation of PcG target
genes that are generally suppressed in stem cells [77,88]. We
propose that in some circumstances pathogens, acting directly or
indirectly, might have a similar effect.
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in endothelial cells [10]. These included the promoter of the
tumour suppressor gene encoding H-cadherin (CDH13), a
gene that is methylated in several types of cancer [11]. The
CDH13 regulatory locus was also substantiallymethylated
in KSHV-positive BCBL-1 PEL-derived cells, so it is
possible LANA recruits DNMT3A and initiates de novo
DNA methylation in B cell lymphomagenesis [10]. It
remains unclear how LANA is targeted to CDH13 (or other
repressed promoters), but its ability to interact with other
chromatin modifying proteins might provide clues. The
capacity of LANA to associate with the corepressors
mSin3, SAP30 and CIR [12], and in particular the histone
H3 lysine 9 (H3K9) methyltransferase SUV39H1 [13], is
consistent with LANA playing a role in transcriptional
repression via histone modification, which could precede
DNA methylation (Figure 1). Moreover, the ability of
LANA to bind heterochromatin protein (HP)1 and the
methyl CpG binding protein MeCP2 as well as DNMTs
[10,14,15], suggests that it might coordinate repressive
histone modifications with DNA methylation.
More recently it was reported that LANA also binds to
the promoter of the gene encoding the transforming growth
factor (TGF)-b type II receptor (TGF-bRII) leading to DNA
methylation and downregulation of transcription [16]. This
epigenetic repression resulted in abrogation of TGF-b
signalling, which could be rescued by ectopic expression
of TGF-bRII. Because TGF-b signalling is generally anti-
proliferative and/or pro-apoptotic in B cells [17], LANA
probably influences latency and lymphoma development
by epigenetic disruption of this pathway and concomitant
enhancement of cell survival. Treatment with the DNMT
inhibitor 5-aza-2-deoxycytidine increased TGF-bRIIexpression and made KSHV-positive PEL cells susceptible
to TGF-b-mediated growth arrest and apoptosis,
suggesting a novel approach to therapy [16].
Furthermore, an investigation into the roles of KSHV
encoded miRNAs revealed that ectopic expression of miR-
K12–4-5p1 could indirectly increase the levels of DNMT1,
DNMT3A and DNMT3B mRNAs [18]. Because the latent
state of the viral episome requires DNA methylation, it
was suggested this increase in DNMTs is necessary to
maintain viral latency, but of course the increased DNA
methyltransferase activity could also facilitate CpG meth-
ylation of host cell genes such as CDH13 and TGF-bRII.
Therefore, it is possible that the interactions of KSHV
factors with host chromatin modifiers and the epigenetic
reprogramming of infected cells is also associated with a
requirement of KSHV to epigenetically regulate its own
genome.
EBV
EBV is associated with several human tumours of B cell, T
cell and epithelial origin, including EBV-associated Bur-
kitt’s lymphoma (BL), post-transplant lymphoproliferative
disease, diffuse large B cell lymphoma, some forms of
Hodgkin’s lymphoma, and the epithelium-derived naso-
pharyngeal carcinoma (NPC) and gastric carcinoma (GC)
[19,20].
In vitro, EBV can very efficiently induce the activation
and continuous proliferation of resting human B cells. The
resulting lymphoblastoid cell lines (LCLs) carry the viral
genome as extrachromosomal episomes, and express only
nine latency-associated EBV proteins. These include six
EB nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C and LP) and
three latent membrane proteins (LMP1, 2A and 2B), and
there are also several untranslated RNA species [20,21]. As
we shall see, several of these proteins are probably
involved in epigenetic modification of the host genome.
Data on the persistence of EBV in humans are consist-
ent with the viral genome residing long-term in a resting
memory B cell population. It is now considered probable
that to establish persistence, EBV initially infects resting
(naive) B cells and drives these to proliferate as activated B
blasts. This expanding infected B blast population then
migrates into germinal centres, where they differentiate to
become centroblasts, centrocytes and finally resting mem-
ory B cells. Although the precise series of events that the
EBV-positive B cells undergo to reach the memory com-
partment is unknown, it appears to involve regulated
shutdown of latent protein expression from an initial state
called latency III (as found in LCLs), via latency II (where
only LMP1, LMP2 andEBNA1 are expressed) until latency
0, a state in quiescent memory B cells in which no EBV
proteins can be detected. Occasionally memory cells divide
and EBNA1 is transiently expressed to ensure mainten-
ance of the viral episome (a state known as latency I)
[19,22].
Because evidence indicated that expression of EBNA3
in BL cells dramatically enhanced their survival potential
[23,24], recombinant EBNA3 knockout (KO) viruses were
used to explore regulators of apoptosis that might be
deregulated by EBV and contribute to this phenotype. This
identified the gene encoding BIM (BCL2L11) as a target441
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requiring the functional cooperation of the EBNAs 3A
and 3C [25]. BIM is a potent inducer of apoptosis and a
crucial regulator of lymphocyte survival. Reduced expres-
sion of BIM enhances lymphomagenesis in mice and
humans, and plays an important role in the pathogenesis
of BL [26].
Subsequently, it was shown that EBV-mediated repres-
sion of BIM transcription initially involves the epigenetic
modification H3K27me3 (histone H3 trimethylated at
lysine 27), probably through polycomb repressive complex
(PRC)2, a known mediator of this modification in humans
(Figure 1, Glossary). The binding of PRC2 to the BIM
promoter and trimethylation of H3K27 might then be
followed by DNA methylation of sites within the CpG
island that flanks the BIM transcriptional initiation site
[27]. H3K27me3 has recently been confirmed as a bone fide
heritable, repressive histone modification that often pre-
cedes DNA methylation in cancer (Figure 1, Box 1). There-
fore, a working hypothesis is that EBV can epigenetically
reprogramBcells and their progeny in thisway, so that they
aremoreprone tobecomecancerous,whichsuggestsamodel
of how the EBNA3s might contribute to the pathogenesis of
BL [19,25,27,28]. Briefly, because preventing the induction
of BIM by the translocated and deregulated proto-oncogene
MYC can be a crucial event in the development of BL,
repression ofBIM transcriptionbyEBNA3Aand3C is likely
to make an important contribution to the progression of
EBV-positive BL. Furthermore, because newly infected B
cells express EBNA2, which constitutively activates the
expression ofMYC [29], EBNA3A andEBNA3Cmight have
evolved this repressor activity to prevent EBNA2/MYC-
induced, BIM-mediated apoptosis during the establishment
of normal EBV latency and persistence.
Consistent with the BIM study linking EBV with the
polycomb system, it was recently shown that EBNA3A and
EBNA3C also functionally interact in polycomb-mediated
repression of the tumour suppressor gene encoding the
cyclin-dependent kinase inhibitor p16INK4A [30]. This
repression of p16INK4A not only overcomes cell cycle arrest
and senescence in EBV infected B cells, butmight also pave
the way for DNAmethylation of p16INK4A control elements
during lymphomagenesis.
BIM and p16INK4A are not the only reported cases of
epigenetic control by EBV. In epithelial cell clones expres-
sing LMP1, increased DNA methylation associated with
repressed transcriptionwas found at the promoter of the E-
cadherin gene (CDH1) [31]. Similar to H-cadherin, E-cad-
herin is an adhesion molecule that affects tumour inva-
siveness and is frequently epigenetically repressed in
human carcinoma [5,32]. The increased DNA methylation
was apparently associated with LMP1-mediated induction
of DNMT1, DNMT3A and DNMT3B, probably via the c-
Jun N-terminal kinase 1 pathway. However, it was not
reported whether this general increase in DNA methyl-
transferase activity led to the CpG methylation of other
tumour suppressor genes, nor whether LMP1-mediated
repression of E-cadherin expression is a common feature
of NPC. Also in the epithelial cell context, GC tumours
carrying latent EBV show increased promoter methylation
of genes encoding the p16INK4A, p14ARF, p73, E-cadherin442and PTEN tumour suppressors, relative to EBV-negative
GC. It has been suggested that these epigenetic changes
could be caused by elevated levels of DNMT1, which in
these cells might be induced by the expression of EBV
LMP2 ([33] and references therein).
Generally, it seems that EBV has established epigenetic
strategies to alter host gene expression to facilitate its life
cycle. In B cells, EBNA3 proteins enhance cell survival and
proliferation. In epithelial cells, the LMPs appear to be
more important. In each case, the infected cells appear
more likely to undergo malignant transformation.
Hepatitis B virus
Hepatitis B virus (HBV) is associated with hepatocellular
carcinoma (HCC), and several studies have indicated that
the presence of HBV in HCC correlates with aberrant DNA
methylation of the host genome [34–37]. HBV infected cells
and HCC tumours show elevated expression of DNMT1,
DNMT3A and DNMT3B relative to uninfected cells and
matched normal tissues, respectively [38]. Because over-
expression of HBV X antigen (HBXAg), another nuclear
oncoprotein, can induce DNMT1 and DNMT3A [39,40], it
has been suggested that this viral protein is responsible for
what has been described as a ‘methylator’ phenotype in
HBV-positive HCC. Consistent with this hypothesis,
HBXAg can repress transcription from and initiate the
CpG methylation of E-cadherin and p16INK4A gene regu-
latory elements [35,41,42]. In both cases, this repression is
thought to be a consequence of HBXAg-mediated induction
of DNMT1.
Human papillomavirus
There are over 100 types of human papillomavirus (HPV)
and several, such asHPV16 and 18, are associatedwith the
development of malignancies that include cervical carci-
noma. It has recently been reported that a keratinocyte cell
line carrying HPV16 episomes has reduced levels of E-
cadherin [43]. The oncoprotein E7 was essential for this
downregulation, whichwas reversible after treatmentwith
the DNMT inhibitor 5-aza-deoxycytidine [43]. Although
the precise mechanism was not described, E7 was shown
to modulate DNMT1 levels [43] and has previously been
shown to bind directly to DNMT1 and precipitate DNA
methyltransferase activity [44]. In addition, because it
disrupts the Rb-E2F pathway, E7 can induce expression
of the H3K27 methyltransferase EZH2 [45]. Increases in
EZH2 have been reported in several types of cancer, and
might be associatedwith theDNAmethylation of polycomb
target genes (Box 1). It is therefore intriguing that
p16INK4A, which is normally repressed in cycling cells by
EZH2 via H3K27me3 and frequently undergoes DNA
hypermethylation in cancer, is often overexpressed in
HPV-positive carcinoma [4,46,47].
The presence of HPV in cervical carcinoma-derived cells
also correlates with DNA hypermethylation of CpG islands
at the 3.3 kb repeats in the subtelomeric regions of
multiple chromosomes [48]. In particular DUX4, which
is encoded by one of these regions (4q35), is downregulated
in a significant percentage of HPV-positive cells [48].
DUX4 is a proapoptotic protein when overexpressed in
cells, so it could act as a tumour suppressor [49].
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associated with increased DNA methylation of the promo-
ters of genes encoding two putative tumour suppressors
(BLU and RASSF1) that are adjacent (head to tail) on the
genome [50]. It is not clear how these promoters are
hypermethylated or what consequences result, but (RAS
association domain family protein (RASSF)1 is a tumour
suppressor that is silenced in many tumours by DNA
hypermethylation [51].
Simian vacuolating virus 40
Simian vacuolating virus (SV)40 is a polyomavirus that
infects monkeys and humans, and is another oncogenic
virus suspected of inducing epigenetic changes in host
cells. SV40, similar to HPV, is associated with RASSF1
promoter DNA methylation in malignant mesothelioma,
where the presence of SV40 large T-antigen (Tag)
sequences significantly correlates with high levels of
DNA methylation [52]. The same correlation was not
observed between infection and RASSF1 methylation in
small cell lung cancer, where this promoter is also some-
times hypermethylated [53].
Nevertheless, more specific sites of aberrant DNAmeth-
ylation might await discovery in SV40 infected cells,
possibly because expression of large T antigen also upre-
gulates DNMT1, with concomitant increases inDNAmeth-
yltransferase activity and genomic methylation [54]. When
10 different tumour suppressor genes were examined in 90
cases of human lymphoid and hematopoietic malignancies,
the presence of SV40 was found to correlate with promoter
DNA methylation of seven of those genes, including
p16INK4A, p15INK4B and p73 [55]. However, apart from
increasing the level of DNMTs, the mechanism of SV40-
associated CpG methylation of cellular genes is not pre-
sently known.
Adenoviruses
Although adenoviruses generally exhibit a lytic rather
than latent life cycle, the viral oncoprotein small e1a
has been reported to globally restrict histone 3 lysine 18
acetylation (H3K18Ac) and repress transcription of
multiple genes [56,57]. However, it remains to be deter-
mined whether this imparts any sort of epigenetic memory
or leads to more stable repression such as DNA methyl-
ation in infected cells or their progeny.
HIV and human T cell leukaemia virus-1
More than a decade ago it was reported that infection of
CD4+ T cells by either HIV-1 or human T cell leukaemia
virus (HTLV)-1 results in an increase in cellular DNA
methyltransferase activity [58]. This produced a general
increase in cellular DNA methylation and a specific
increase in methylation at the interferon–g promoter,
associated with transcriptional repression. Although it is
still unclear what (if any) contribution this makes to HIV-
associated disease, in HTLV-1-carrying adult T cell leu-
kaemia/lymphoma (ATLL) many of the ‘usual suspect’
tumour suppressor genes, including those encoding
p16INK4A and p73, become hypermethylated [59]. This
‘methylator’ phenotype is associated with disease pro-
gression and crisis, but the mechanism has not beenidentified, so it remains to be determined whether there
is a link with the induction of DNMT activity by HTLV-1
[58,59].
HIV infection of T lymphocytes in culture also causes
promoter methylation of the gene GNE, which encodes a
key enzyme in sialic acid biosynthesis, and represses its
transcription [60]. This might lead to disruption of cell
surface sialylation, which is important in cell–cell recog-
nition and might have important effects on lymphocyte
trafficking.
Paramecium bursaria chlorella virus
Although Paramecium bursaria chlorella virus (PBCV)-1
infects Chlorella green algae and would probably not be
considered a typical pathogen, it is worthy of consideration
because it carries a gene encoding a viral SET (vSET)
domain protein ([61] and references therein). This highly
conserved domain is found in many eukaryotic proteins
that associate with chromatin, including members of the
polycomb protein group, and has histone lysine methyl-
transferase activity [62]. It was revealed that infection
with PBCV-1 significantly increased methylation of
histone H3K27 in its host and rapidly repressed gen-
ome-wide transcription [61]. Perhaps more remarkable,
when vSET was expressed in human HeLa cells, it cata-
lysed H3K27 trimethylation after the depletion of EZH2 by
siRNA [61]. vSET-mediated methylation of H3K27 then
promoted the recruitment of PRC1 on to chromatin,
further demonstrating the conserved nature of the system.
Surprisingly, to date, this is the only viral histone lysine
methyltransferase to be identified.
Bacterial modification of the host epigenome
Some chronic bacterial infections are also associated with
malignancy, themost well-known andwidely studied being
Helicobacter pylori infection of human gastric mucosae (see
below). Moreover, many microbes have evolved ways of
eluding the immune response and, again, epigenetic
changes in host cells have been implicated in these pro-
cesses.
Chlamydophila pneumoniae
An obligate intracellular pathogen that causes acute
respiratory diseases, C. pneumoniae, similar to PBCV-1,
encodes a SET domain protein. The chlamydial SET
domain protein directly interacts with chlamydial histone
H1-like proteins Hc1 and Hc2, and has a histone methyl-
transferase activity capable of methylatingmurine histone
H3 in vitro [63]. Its role in pathogenesis has not been
described. However, genomic DNA sequence analysis
has revealed that a significant number of bacteria have
SET domain genes [63,64], which could presumably have
functions linked to chromatin modelling. However,
because not all will enter the host cell nucleus, it is
probable that they methylate non-chromatin proteins
[65]. One can only speculate that these might also interfere
with host responses and modulate pathogenicity.
Campylobacter rectus
Experiments in which mice were orally infected with C.
rectus revealed bacteria translocated to the placenta from443
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currently, downregulation of the Igf2 gene in the placenta
was found to be associated with higher levels of DNA
methylation at its promoter [66]. Igf2 is an imprinted gene
that is implicated in placental development and fetal
growth [67]. It is known that oral infection with C. rectus
can lead to increased risk of preterm births [68], and it will
therefore be interesting to discover whether this involves
bacteria-mediated epigenetic modifications to the host
genome.
Anaplasma phagocytophilum
This Rickettsiales intracellular pathogen replicates in
human neutrophils and their bone marrow progenitors.
In these cells it has to survive despite the presence of the
multiple antimicrobial mechanisms employed by these
primary defence cells, mechanisms mediated by a number
of so-called ‘defence genes’. In a recent report that assessed
the expression of 23 defence genes after infection of a
monocytic cell line withA. phagocytophilum, 19 were down-
regulated [69]. Histone deacetylase (HDAC)1 expression
was increased in the infected cells, as was its association
with the promoters of most of the affected genes. There was
evidence of histone H3 deacetylation at these sites, and
although there was a concomitant increase in H3 methyl-
ation, it is not yet clear whether stable epigenetic markers
become established [69]. It is nowemerging thatmodulation
of histone acetylation on host defence genes might be a
relatively common feature of bacterial infections, as several
bacteria, includingListeriamonocytogenes,Clostridiumper-
fringens, Streptococcus pneumoniae andMycobacteria spp.,
can alter host histone acetylation and/or HDAC activity
[69,70]. Is it possible that epigenetic reprogramming of
defence genes is a widespread phenomenon?
H. pylori
Infection with this Gram-negative bacterium can result in
chronic gastritis and peptic ulcers, and chronic H. pylori
infection is closely associated with intestinal metaplasia
and the development of gastric cancer [71,72]. In a recent
study, 25 genes and several repetitive DNA elements were
tested for DNA methylation in 212 tissue samples from
gastric lesions, with or without H. pylori infection [73].
There was a good correlation between infection and DNA
methylation at CpG islands in chronic gastritis, and there
was also a correlation between the amount of DNA meth-
ylation and cancer progression. However, the correlation
between the presence of H. pylori and cancer progression
was not entirely consistent [73]. This could be because
DNA methylation caused by infection in chronic gastritis
does not always lead to carcinogenesis, or because the
heritable nature of the epigenetic changes renders the
continual presence of the infection unnecessary.
Co-cultivation of human gastric cell lines with H. pylori
induced DNA methylation of CDH1, the E-cadherin gene
[74]. The effect is probably indirect and thought to be
through the action of the inflammatory cytokine interleu-
kin-1b, which is known to induce CpG methylation and is
upregulated by H. pylori [74,75]. Another recent study
using a small animal model also indicated that it is the
infection-associated inflammatory response, rather than444H. pylori itself, that is responsible for the induction of
aberrant DNA methylation in cells of the gastric mucosa
[76]. These data are consistent with the demonstration
that polycomb target genes preferentially undergo aber-
rant DNA methylation during chronic inflammation of the
intestine and in intestinal cancer (Box 1) [77].
It might be significant that all the bacteria that aremost
clearly associated with stable epigenetic modifications of
host genes (e.g.C. pneumoniae, C. rectus, andH. pylori) are
also linked to chronic disease.
Concluding remarks and future directions
It is easy tounderstand fromtheexamplesofpersistentviral
infections (e.g. KSHV and EBV) how the ability to epigen-
etically influence host gene expression could have evolved
and how it might play a major role in the pathogenesis of
chronic disease. Similarly, although the mechanisms are
less well understood, the idea of epigenetic changes in host
cells associated with chronic bacterial infections (e.g. H.
pylori) contributing to disease is conceptually satisfying.
What is less obvious is the significance of such heritable
changes in host cell behaviour during acute pathogen-
mediated disease. Perhaps a unifying theme is the modu-
lationof the immuneresponse, inflammationand intracellu-
lar host defences. This requires further exploration.
In summary, from data available currently, several
themes are emerging.
1. Latent viral infection can (de)regulate patterns of
repressive histone modifications that could then
precipitate aberrant DNA methylation and the repro-
gramming of infected cells and their progeny. This can
involve the repression of tumour suppressor genes, for
which there will be strong selection in the development
in cancer. Examples include KSHV and EBV.
2. Infection by diverse viruses appears to induce expres-
sion of DNMTs and/or polycomb group (PcG) proteins
such as EZH2. Examples include KSHV, EBV, HBV,
HIV-1, HTLV-1, HPV, SV40 and adenoviruses. The
important caveat with these data is that the expression
of DNMTs and EZH2 correlates with cell proliferation
rate; therefore a high level of expression might be a
consequence of the proportion of cells proliferating in
tumours and/or chronically inflamed tissue.
3. At least one virus, PBCV-1, and perhapsmany bacteria,
including C. pneumoniae, [63,64] encode SET domain
proteins that could methylate histones and so alter the
organisation of host chromatin. However they might
target many non-histone proteins for methylation.
4. Stimulation of host HDAC activity might be a common
feature of microbial infection. This could contribute to
the epigenetic repression of ‘defence genes’ in host cells.
The possibility that this occurs in non-infected bystan-
der cells responding to the uptake of soluble factors is
also worth exploring.
5. Inflammation, whether or not it is induced by infection,
can be a potent initiator of aberrant methylation of PcG
target genes. Therefore chronic inflammation might
predispose cells to malignant transformation.
6. The stable heritable nature of epigenetic change
implies that the initial inducers of transcriptional
repression and chromatin modification need only be
Review Trends in Microbiology Vol.18 No.10expressed transiently. Although inmost cases, effectors
are continuously present, this provides a rational
explanation for potential ‘hit and run’ mechanisms in
infectious disease pathogenesis.
For many pathogens, it is very difficult to make even
educated guesses about the extent or the mechanics of
epigenetic change they might induce. Currently available
data largely provide snapshots of what is happening to
‘usual suspect’ host genes after infection. More compre-
hensive global studies are now necessary and possible.
We are now in the era of epigenetics [78,79], and tech-
nologies for global analyses are being developed at a
remarkable pace. Various methods are available for deter-
mining genome-wide DNA methylation signatures [80]
and methods such as ChIP–chip (ChIP, coupled with
expression microarray technology) and ChIP-seq (ChIP,
coupled with deep-sequencing analysis) for mapping global
chromatin modifications are now well established [81].
Over the coming months and years, these approaches will
be invaluable for exploring the contribution that infections
make to the epigenetic landscape and demonstrating the
dynamic nature of the human ‘epigenome’.
Note added in proof
While this article was in the final stages of preparation,
Soria et al. (Nature 466, 1076–1081, 2010), showed that
the E4-ORF3 protein of oncogenic adenoviruses induces
widespread epigenetic silencing of tumour suppressor
p53-target genes.
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